Jean-Christophe Tellier has taken up the role as CEO of UCB, effective January 1, 2015, succeeding Roch Doliveux. He is also chairman of UCB’s Executive Committee and member of the board of directors. Roch Doliveux stepped down on December 31, 2014 after leading UCB for the last 10 years. UCB’s board of directors granted him the titles of honorary member of the board and honorary chairman of the Executive Committee. Jean-Christophe Tellier joined the company in 2011 and has a 25-year career in the biopharmaceutical industry.
UCB’s leadership team, effective 1 February 2015, will have a clear focus on key disease or domain expertise areas. UCB's Executive Committee will be structured as follows, each unit being led by an executive vice president reporting to Jean-Christophe Tellier, CEO and chairman of the Executive Committee.
Patient Value Units:
New Medicines : Ismail Kola, New Medicines head and chief scientific officer
Neurology : Jeff Wren, Patient Value Unit head, previously head of UCB’s North American region
Immunology : Emmanuel Caeymaex, Patient Value Unit head, previously head of UCB’s Cimzia team
Bone disorders : this position is still to be filled and will be led ad interim by Iris Loew Friedrich.
Patient Value Practices:
Strategic Marketing : Bharat Tewarie, chief marketing officer. A physician with strong industry experience, he joins UCB from Merck-Serono where he was senior vice president, head of Global Business Franchise Neurology & Immunology and head of Global Business Franchise Medical Devices Development and Medical
Iris Loew Friedrich, chief medical officer
Patient Value Operations:
Geographic Operations, Established Brands, Technical Operations and Business Development: Mark McDade, chief operating officer
Patient Value Functions:
Legal: Anna Richo, general counsel